|
Sep 30
|
Galapagos receives transparency notification from EcoR1 Capital
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Jun 14
|
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
|
|
Jun 14
|
Retail investors are Galapagos NV's (AMS:GLPG) biggest owners and were hit after market cap dropped €74m
|
|
May 6
|
Galapagos NV (NASDAQ:GLPG) Q1 2024 Earnings Call Transcript
|
|
May 4
|
Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
|
|
Jan 2
|
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
|
|
Dec 19
|
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
|
|
Dec 9
|
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
|
|
Dec 7
|
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
|
|
May 2
|
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
|